Literature DB >> 19454523

Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.

Che-Kim Tan, Chih-Cheng Lai, Chun-Hsing Liao, Chien-Hong Chou, Hsiao-Leng Hsu, Yu-Tsung Huang, Po-Ren Hsueh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19454523     DOI： 10.1093/jac/dkp174

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  13 in total

1.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  Kobkul Chotikanatis; Stephan A Kohlhoff; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Authors:  Heather J Adam; Nancy M Laing; C Richard King; Ben Lulashnyk; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

3.  Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.

Authors:  Zhaoxia Li; Youning Liu; Rui Wang; Aimin Li
Journal:  World J Microbiol Biotechnol       Date:  2014-08-18       Impact factor: 3.312

4.  Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.

Authors:  Chih-Cheng Lai; Wei-Lun Liu; Wen-Chien Ko; Yen-Hsu Chen; Hon-Ren Tan; Yu-Tsung Huang; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

5.  Direct observation therapy with appropriate treatment regimens was associated with a decline in second-line drug-resistant tuberculosis in Taiwan.

Authors:  J-Y Chien; C-C Tsou; S-T Chien; C-J Yu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-12       Impact factor: 3.267

6.  Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.

Authors:  Hana M El Sahly; Larry D Teeter; Kenneth C Jost; Denise Dunbar; Justin Lew; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

7.  In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.

Authors:  J-C Yang; P-I Lee; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-25       Impact factor: 3.267

8.  Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.

Authors:  Dirkie J J van Rensburg; Reury-Perng Perng; Ismail H Mitha; Andrè J Bester; Joseph Kasumba; Ren-Guang Wu; Ming-Lin Ho; Li-Wen Chang; David T Chung; Yu-Ting Chang; Chi-Hsin R King; Ming-Chu Hsu
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

9.  Clinical effects of gemifloxacin on the delay of tuberculosis treatment.

Authors:  Seo Yun Kim; Jae-Joon Yim; Jong Sun Park; Sung Soo Park; Eun Young Heo; Chang-Hoon Lee; Hee Soon Chung; Deog Kyeom Kim
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

Review 10.  Nemonoxacin: first global approval.

Authors:  Raewyn M Poole
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.